scholarly journals The N-Terminal End of the Catalytic Domain of Src Kinase Hck Is a Conformational Switch Implicated in Long-Range Allosteric Regulation

Structure ◽  
2005 ◽  
Vol 13 (11) ◽  
pp. 1715-1723 ◽  
Author(s):  
Nilesh K. Banavali ◽  
Benoît Roux
2008 ◽  
Vol 283 (44) ◽  
pp. 29699-29705 ◽  
Author(s):  
Xiu-Jun Zhang ◽  
Karyn B. Cahill ◽  
Arye Elfenbein ◽  
Vadim Y. Arshavsky ◽  
Rick H. Cote

2001 ◽  
Vol 21 (24) ◽  
pp. 8414-8427 ◽  
Author(s):  
Marie W. Wooten ◽  
Michel L. Vandenplas ◽  
M. Lamar Seibenhener ◽  
Thangiah Geetha ◽  
Maria T. Diaz-Meco

ABSTRACT Atypical protein kinase C (PKC) isoforms are required for nerve growth factor (NGF)-initiated differentiation of PC12 cells. In the present study, we report that PKC-ι becomes tyrosine phosphorylated in the membrane coincident with activation posttreatment with nerve growth factor. Tyrosine phosphorylation and activation of PKC-ι were inhibited in a dose-dependent manner by both PP2 and K252a, src and TrkA kinase inhibitors. Purified src was observed to phosphorylate and activate PKC-ι in vitro. In PC12 cells deficient in src kinase activity, both NGF-induced tyrosine phosphorylation and activation of PKC-ι were also diminished. Furthermore, we demonstrate activation of src by NGF along with formation of a signal complex including the TrkA receptor, src, and PKC-ι. Recruitment of PKC-ι into the complex was dependent on the tyrosine phosphorylation state of PKC-ι. The association of src and PKC-ι was constitutive but was enhanced by NGF treatment, with the src homology 3 domain interacting with a PXXP sequence within the regulatory domain of PKC-ι (amino acids 98 to 114). Altogether, these findings support a role for src in regulation of PKC-ι. Tyrosine 256, 271, and 325 were identified as major sites phosphorylated by src in the catalytic domain. Y256F and Y271F mutations did not alter src-induced activation of PKC-ι, whereas the Y325F mutation significantly reduced src-induced activation of PKC-ι. The functional relevance of these mutations was tested by determining the ability of each mutant to support TRAF6 activation of NF-κB, with significant impairment by the Y325F PKC-ι mutant. Moreover, when the Y352F mutant was expressed in PC12 cells, NGF's ability to promote survival in serum-free media was reduced. In summary, we have identified a novel mechanism for NGF-induced activation of atypical PKC involving tyrosine phosphorylation by c-Src.


2017 ◽  
Vol 8 (1) ◽  
Author(s):  
David Haselbach ◽  
Jil Schrader ◽  
Felix Lambrecht ◽  
Fabian Henneberg ◽  
Ashwin Chari ◽  
...  

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Bodo Sander ◽  
Wenshan Xu ◽  
Martin Eilers ◽  
Nikita Popov ◽  
Sonja Lorenz

The human ubiquitin ligase HUWE1 has key roles in tumorigenesis, yet it is unkown how its activity is regulated. We present the crystal structure of a C-terminal part of HUWE1, including the catalytic domain, and reveal an asymmetric auto-inhibited dimer. We show that HUWE1 dimerizes in solution and self-associates in cells, and that both occurs through the crystallographic dimer interface. We demonstrate that HUWE1 is inhibited in cells and that it can be activated by disruption of the dimer interface. We identify a conserved segment in HUWE1 that counteracts dimer formation by associating with the dimerization region intramolecularly. Our studies reveal, intriguingly, that the tumor suppressor p14ARF binds to this segment and may thus shift the conformational equilibrium of HUWE1 toward the inactive state. We propose a model, in which the activity of HUWE1 underlies conformational control in response to physiological cues—a mechanism that may be exploited for cancer therapy.


2013 ◽  
Vol 104 (2) ◽  
pp. 679a
Author(s):  
Pei-Hsuan Chu ◽  
Andrei V. Karginov ◽  
David G. Shirvanyants ◽  
Nikolay V. Dokholyan ◽  
Klaus M. Hahn
Keyword(s):  

2006 ◽  
Vol 281 (12) ◽  
pp. 8183-8189 ◽  
Author(s):  
Sungsoo Lee ◽  
Marina K. Ayrapetov ◽  
David J. Kemble ◽  
Keykavous Parang ◽  
Gongqin Sun

2016 ◽  
Author(s):  
Lili X Peng ◽  
Morgan Lawrenz ◽  
Diwakar Shukla ◽  
Grace W Tang ◽  
Vijay S Pande ◽  
...  

Recent molecular dynamics (MD) simulations of the catalytic domain of the c-Src kinase revealed intermediate conformations with a potentially druggable allosteric pocket adjacent to the C-helix, bound by 8-anilino-1-naphthalene sulfonate. Towards confirming the existence of this pocket, we have developed a novel lead enrichment protocol using new target and lead enrichment software to identify sixteen allosteric lead ligands of the c-Src kinase. First, Markov State Models analysis was used to identify the most statistically significant c-Src target conformations from all MD-simulated conformations. The most statistically relevant candidate MSM targets were then prioritized by assessing how well each reproduced binding poses of ligands specific to the ATP-competitive and allosteric pockets. The top-performing MSM targets, identified by receiver-operating curve analysis, were then used to screen the ZINC library of 13 million ″clean, drug-like ligands″, all of which prioritized based on their empirical scoring function, binding pose consistency across MSM targets, and strong hydrogen bonding and hydrophobic interactions with Src residues. The FragFEATURE knowledgebase of fragment-protein pocket interactions was then used to identify fragments specific to the ATP-competitive and allosteric pockets. This information was used to identify seven Type II and nine Type III lead ligands with binding poses supported by fragment predictions. Of these, Type II lead ligands, ZINC13037947 and ZINC09672647, and Type III lead ligands, ZINC12530852 and ZINC30012975, exhibited the most favorable fragment profiles and are recommended for further experimental testing for the existence of the allosteric pocket in Src.


Sign in / Sign up

Export Citation Format

Share Document